Uzbekistan Pharmaceuticals & Healthcare Report
We maintain the view that risk-averse pharmaceutical, healthcare and medical device companies should avoid Uzbekistan . While the country has a definite need for pharmaceuticals and medical devices, the regulatory environment remains opaque and state-dominated. Moreover, the government is committed to boosting Uzbekistan's domestic capacity for pharmaceutical manufacturing, which is expected to gradually decrease market potential for most generic medicines.
Headline Expenditure Projections
• Pharmaceuticals: UZS853.25bn (US$498mn) in 2011 to UZS993.00bn (US$563mn) in 2012; up 16.4% in local currency terms and 13.0% in US dollar terms. Forecast unchanged from Q412.
• Healthcare: UZS4,081bn (US$2.38bn) in 2011 to UZS4,932bn (US$2.79bn) in 2012; up 20.8% in local currency terms and 17.4% in US dollar terms. Forecastunchanged from Q4 12.
• Medical devices: UZS155.82bn (US$91mn) in 2011 to UZS179.45bn (US$102mn) in 2012; up 15.2% in local currency terms and 11.8% in US dollar terms. Forecast unchanged from Q412.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/the-pharmaceutical-market-uzbekistan
Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/207539
THE PHARMACEUTICAL MARKET: ESTONIA - REVIEW
Our outlook for the Estonian pharmaceutical market remains unchanged. While epidemiological trends will continue to stimulate the volume development of the market, patent expirations and government encouragement of the consumption of cheaper generic medicine will hamper value growth. The market will remain reliant on imports, which are expected to outperform exports and also the overall market...